Trade Names:ACTH- Powder for Injection 40 units/vial
Trade Names:HP Acthar- Powder for Injection 25 units/vial- Powder for Injection 40 units/vial
Stimulates adrenal cortex to produce and secrete adrenocortical hormones (eg, corticosteroids, glucocorticoids).
T max is within 1 h.
Plasma concentrations begin to decrease after 2 to 4 h.
Diagnostic testing of adrenocortical function; include diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that caused by lupus erythematosus; treatment of nonsuppurative thyroiditis, hypercalcemia associated with cancer, acute exacerbations of multiple sclerosis, tuberculous meningitis when accompanied by antituberculous chemotherapy, trichinosis with neurologic or myocardial involvement, and treatment of glucocorticoid responsive rheumatic, collagenous, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, and GI diseases.
Treatment of infantile spasms.
Scleroderma; osteoporosis; systemic fungal infections; ocular herpes simplex; recent surgery; history or presence of peptic ulcer; CHF; hypertension; sensitivity to porcine proteins; conditions accompanied by primary adrenocortical insufficiency or adrenocortical hyperfunction; IV administration is contraindicated, except in treatment of idiopathic thrombocytopenic purpura or diagnostic testing of adrenocortical function.
IM/Subcutaneous 40 to 80 units every 24 to 72 h. Not suitable for IV use.Acute Exacerbations of Multiple Sclerosis
IM 80 to 120 units/day for 2 to 3 wk.
Medication may be given via IM or subcutaneous route. Do not use IV route.
Effects of these agents may be antagonized in myasthenia gravis.Barbiturates
May decrease effects of corticotropin.
May decrease I 131 uptake; possible suppression of skin test reactions; falsely decreased urinary estradiol and estriol concentrations with Brown method; falsely decreased urinary estrogen concentrations with colorimetry and fluorometry.
Hypertension; CHF; necrotizing angiitis.
Convulsions; vertigo; headache; increased intracranial pressure with papilledema; pseudotumor cerebri.
Impaired wound healing; petechiae and ecchymoses; increased sweating; hyperpigmentation; thin, fragile skin; facial erythema; acne.
Posterior subcapsular cataracts; increased IOP; glaucoma with possible optic nerve damage; exophthalmos.
Pancreatitis; ulcerative esophagitis; abdominal distention; peptic ulcer.
Negative nitrogen balance because of protein catabolism; fluid and electrolyte disturbances (eg, sodium and fluid retention, potassium and calcium loss, hypokalemic alkalosis); antibody production and loss of stimulatory effect of ACTH with prolonged use.
Infection; musculoskeletal disturbances (eg, weakness, myopathy, loss of muscle mass, osteoporosis, vertebral compression fractures, pathologic fracture of long bones, aseptic necrosis of femoral and humeral heads); endocrine abnormalities (eg, menstrual irregularities, growth suppression in children, hirsutism, cushingoid state, glucose intolerance, decreased carbohydrate tolerance, increased requirement for insulin or oral hypoglycemic agent in patients with diabetes, secondary adrenocortical, pituitary unresponsiveness.
In patients with diabetes, monitor blood glucose frequently because dosage of insulin or oral hypoglycemic agent may need to be increased.Adverse reactions
Report any of the following to health care provider: fluid retention; muscle weakness; abdominal pain; seizures; headache; adrenal insufficiency (eg, fatigue, anorexia, nausea, vomiting, diarrhea, weight loss, weakness, dizziness); visual disturbances; cushingoid symptoms.
Category C .
Because prolonged use inhibits skeletal growth, careful monitoring is necessary.
Drug may elevate BP, cause salt and water retention, and increase potassium and calcium excretion.
Live vaccine immunization is usually contraindicated, especially with high doses of corticotropin.
Drug may mask signs of infection; resistance to infection may be decreased.
May lead to irreversible adverse reactions. Complications are dependent on dose and duration of treatment. Prolonged use increases risk of hypersensitivity reactions and ocular effects.
Perform skin testing in patients with suspected sensitivity to porcine proteins. Observe for sensitivity reactions during or after administration.
Increased dosage of rapid-acting corticosteroid may be needed before, during, and after stressful situations.
Copyright © 2009 Wolters Kluwer Health.